“Endothelial Dysfunction in esuscitated ardiac rrest (ENDO-RCA): Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.” - 18/12/19
, Per I. Johansson, MPA, DMSc a, c , Jesper Kjaergaard, Ph.D, DMSc b , Martin Frydland, MD b , Martin A.S. Meyer, MD a , Hanne Hee Henriksen, MD a , Jakob H. Thomsen, MD, Ph.D b , Sebastian C. Wiberg, MD, Ph.D b , Christian Hassager, DMSc b , Sisse R. Ostrowski, Ph.D, DMSc a Abstract |
Objective |
An increasingly recognized prognostic factor for out-of-hospital-cardiac-arrest (OHCA) patients is the ischemia-reperfusion injury after restored blood circulation. Endothelial injury is common in patients resuscitated from cardiac arrest and is associated with poor outcome. This study was designed to investigate if iloprost infusion, a prostacyclin analogue, reduces endothelial damage in OHCA patients.
Methods |
50 patients were randomized in a placebo controlled double-blinded trial and allocated 1:2 to 48-hours iloprost infusion, (1 ng/kg/min) or placebo (saline infusion). Endothelial biomarkers (soluble thrombomodulin (sTM), sE-selectin, syndecan-1, soluble vascular endothelial growth factor (sVEGF), vascular endothelial cadherine (VEcad), nucleosomes) and sympathoadrenal activation (epinephrine/norepinephrine) from baseline to 48 and 96-hours were evaluated.
Results |
Iloprost infusion did not influence endothelial biomarkers by the 48-hour endpoint. A rebound effect was observed with higher biomarker plasma values in the iloprost group (sTM p=0.02; Syndecan p=0.004; nucleosomes p<0.001; VEcad p<0.03) after 96-hours. There was a significant difference in 180-day mortality in favor of placebo. There was no difference regarding total adverse events between groups (p=0.73). Two patients were withdrawn in the iloprost group due to hypotension.
Conclusions |
The administration of low-dose iloprost (1ng/kg/min) to OHCA patients did not significantly influence endothelial biomarkers as measured by the 48- hour endpoint. A rebound effect was however observed in the 96-hour statistical model, with increasing endothelial biomarker levels after cessation of the iloprost-infusion.
Le texte complet de cet article est disponible en PDF.Plan
| Study Site: Dept. of Cardiology, Rigshospitalet, 2143, Blegdamsvej 9, DK-2100 Copenhagen, Denmark Reprint: No reprints ordered Conflicts of Interest: Authors have disclosed that they do not have any conflicts of interest. Trial Registration: Trial registration at clinicaltrials.gov (identifier NCT02685618) on 18-02-2016. |
Vol 219
P. 9-20 - janvier 2020 Retour au numéro
Article précédent
- Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors: Methodological aspects of the Dutch late effects after childhood cancer (LATER) cardiology study
- Jan M. Leerink, E. Lieke A.M. Feijen, Helena J.H. van der Pal, Wouter E.M. Kok, Annelies M.C. Mavinkurve-Groothuis, Livia Kapusta, Yigal M. Pinto, Angela H.E.M. Maas, Louise Bellersen, Arco J. Teske, Cécile M. Ronckers, Marloes Louwerens, Elvira C. van Dalen, Eline van Dulmen-den Broeder, Lilian Batenburg, Margriet van der Heiden-van der Loo, Marry M. van den Heuvel-Eibrink, Flora E. van Leeuwen, Andrica C.H. de Vries, Gert Weijers, Chris L. de Korte, Jacqueline J. Loonen, Sebastian J.C.M.M. Neggers, A.B. Birgitta Versluys, Wim J.E. Tissing, Leontien C.M. Kremer, on behalf of the LATER Study Group
- Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation
- Zak Loring, Peter Shrader, Larry A. Allen, Rosalia Blanco, Paul S. Chan, Michael D. Ezekowitz, Gregg C. Fonarow, James V. Freeman, Bernard J. Gersh, Kenneth W. Mahaffey, Gerald V. Naccarelli, Karen Pieper, James A. Reiffel, Daniel E. Singer, Benjamin A. Steinberg, Laine E. Thomas, Eric D. Peterson, Jonathan P. Piccini
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?